Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 1 | Journal for ImmunoTherapy of Cancer

Fig. 1

From: Fusion of the dendritic cell-targeting chemokine MIP3α to melanoma antigen Gp100 in a therapeutic DNA vaccine significantly enhances immunogenicity and survival in a mouse melanoma model

Fig. 1

Systemic immune parameters of vaccine groups in prophylactic vaccination setting. Mice were vaccinated three times at 1 week intervals with endotoxin-free PBS, dMIP3α-gp100, and MIP3α-gp100 fusion vaccine. Analysis occurred 2 weeks post third vaccination. Data represent two independent experiments with 3–5 mice per group per experiment. a Analysis of relative antibody production against B16F10 cells. In-Cell ELISA performed utilizing fixed B16F10 cells as antigens. Experimental data are shown at a 1:2000 serum dilution after 30-min colorimetric development. Absorbance values from pre-immune mice were subtracted from post immune mice to obtain the delta absorbance. All groups were significantly different from each other by ANOVA. b-c Analysis of splenic CD8+ T cells reactive to ex vivo stimulation by gp10025-33 peptide. Activation was signaled by cytoplasmic IFN-γ accumulation as measured by Intracellular Cytokine Staining Flow Cytometry. Panel b shows the data as percentage of CD3+ splenocytes. Panel c estimates the total number of reactive CD3 + CD8+ splenocytes by extrapolating flow cytometric data to measured splenic total cell counts. For both panels, all groups differ significantly from each other, as determined by by ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001

Back to article page